Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Oral Health Reports
Erschienen in: Current Oral Health Reports 2/2016

01.06.2016 | Oral Neoplasia (F Alawi and A Le, Section Editors)

Benign Odontogenic Tumors: Origins, Immunophenotypic Features, and Genetic Alterations

verfasst von: Chunmiao Jiang, Qilin Xu, Qunzhou Zhang, Steven Wang, Lee R. Carrasco, Anh D. Le

Erschienen in: Current Oral Health Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Odontogenic tumors are lesions derived from the epithelial and/or mesenchymal elements of the tooth-forming apparatus and are therefore found within the jaw bone or soft tissue overlying teeth. These tooth development-associated tumors are generally benign, but several odontogenic tumors are capable of aggressive growth and locally invasive behavior with a high rate of recurrence. Benign odontogenic tumors can pose diagnostic challenges because of overlapping histology, a lack of distinct phenotypic and molecular features, and an unclear pathogenesis of the tumors. In this article, we will review the possible origins, immunophenotypic features, and genetic alterations of the common benign odontogenic tumors.
Literatur
1.
Barnes L. Pathology and genetics of head and neck tumours. Vol. 9. Lyon: IARC; 2005.
2.
Press SG. Odontogenic tumors of the maxillary sinus. Curr Opin Otolaryngol Head Neck Surg. 2008;16(1):47–54.CrossRefPubMed
3.
Sekerci AE et al. Odontogenic tumors: a collaborative study of 218 cases diagnosed over 12 years and comprehensive review of the literature. Med Oral Patol Oral Cir Bucal. 2015;20(1):e34–44.CrossRefPubMedPubMedCentral
4.
Jing W et al. Odontogenic tumours: a retrospective study of 1642 cases in a Chinese population. Int J Oral Maxillofac Surg. 2007;36(1):20–5.CrossRefPubMed
5.
Gorlin RJ, Chaudhry AP, Pindborg JJ. Odontogenic tumors. Classification, histopathology, and clinical behavior in man and domesticated animals. Cancer. 1961;14:73–101.CrossRefPubMed
6.
Takeda Y, Kuroda M, Suzuki A. Ameloblastoma of mucosal origin. Acta Pathol Jpn. 1988;38(8):1053–60.PubMed
7.
Kim J, Ellis GL. Dental follicular tissue: misinterpretation as odontogenic tumors. J Oral Maxillofac Surg. 1993;51(7):762–7. discussion 767–8.CrossRefPubMed
8.•
Nagamalini BR et al. Origin of ameloblastoma from basal cells of the oral epithelium-establishing the relation using neuroectodermal markers. J Clin Diagn Res. 2014;8(10):ZC44. The neuroectoderm, ameloblastoma and the basal layer of the oral epithelium have strong relationship with each other, which favours the hypothesis that the basal cell layer of oral mucosa may be a main source of ameloblastoma, espeically in the non-tooth bearing area.
9.
Gagari E. Neuroendocrine markers in ameloblastoma: an immunohistochemical study of 32 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(2):194.CrossRef
10.
Takeda Y et al. Immunohistochemical expression of neural tissue markers (neuron-specific enolase, glial fibrillary acidic protein, S100 protein) in ameloblastic fibrodentinoma: a comparative study with ameloblastic fibroma. Pathol Int. 2000;50(8):610–5.CrossRefPubMed
11.
Philipsen HP et al. Peripheral ameloblastoma: biological profile based on 160 cases from the literature. Oral Oncol. 2001;37(1):17–27.CrossRefPubMed
12.
Kishino M et al. A immunohistochemical study of the peripheral ameloblastoma. Oral Dis. 2007;13(6):575–80.CrossRefPubMed
13.
Ide F et al. Peripheral ameloblastoma in-situ: an evidential fact of surface epithelium origin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(5):763–7.CrossRefPubMed
14.
Ide F. Peripheral ameloblastoma of the buccal mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(5):653–4. author reply 654–5.CrossRefPubMed
15.
Kanzaki H et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res. 2001;80(3):887–91.CrossRefPubMed
16.
Rani CS, MacDougall M. Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Commun. 2000;3(3):145–52.CrossRefPubMed
17.
Sakata M et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. J Bone Miner Res. 1999;14(9):1486–92.CrossRefPubMed
18.
Pripatnanont P et al. In situ hybridisation and immunocytochemical localisation of osteolytic cytokines and adhesion molecules in ameloblastomas. J Oral Pathol Med. 1998;27(10):496–500.CrossRefPubMed
19.
Ahlem B et al. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(5):275–9.CrossRefPubMed
20.
Cavalcante RB et al. Immunohistochemical expression of MMPs 1, 7, and 26 in syndrome and nonsyndrome odontogenic keratocysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(1):99–105.CrossRefPubMed
21.
Cross JJL et al. Value of computed tomography and magnetic resonance imaging in the treatment of a calcifying epithelial odontogenic (Pindborg) tumour. Br J Oral Maxillofac Surg. 2000;38(2):154–7.CrossRefPubMed
22.
Martinez-Mata G et al. Odontogenic myxoma: clinico-pathological, immunohistochemical and ultrastructural findings of a multicentric series. Oral Oncol. 2008;44(6):601–7.CrossRefPubMed
23.
Miyagi SPH et al. Expression of matrix metalloproteinases 2 and 9 in odontogenic myxoma in vivo and in vitro. J Oral Sci. 2008;50(2):187–92.CrossRefPubMed
24.
Olimid DA et al. The evaluation of p16 and Ki67 immunoexpression in ameloblastomas. Rom J Morphol Embryol. 2014;55(2):363–7.PubMed
25.
Lo Muzio L et al. Expression of cell cycle and apoptosis-related proteins in sporadic odontogenic keratocysts and odontogenic keratocysts associated with the nevoid basal cell carcinoma syndrome. J Dent Res. 1999;78(7):1345–53.CrossRefPubMed
26.
Gadbail AR et al. Actual Proliferating Index and p53 protein expression as prognostic marker in odontogenic cysts. Oral Dis. 2009;15(7):490–8.CrossRefPubMed
27.
Razavi SM, Khalesi S, Torabinia N. Investigation of clinicopathological parameters alongside with p53 expression in primary and recurrent keratocysticodontogenic tumours. Malays J Pathol. 2014;36(2):105–13.PubMed
28.
Deyhimi P, Hashemzadeh Z. Study of the biologic behavior of odontogenic keratocyst and orthokeratinaized odontogenic cyst using TGF-alpha and P53 markers. Pathol Res Pract. 2014;210(4):201–4.CrossRefPubMed
29.
Meghji S et al. Interleukin-1: the principal osteolytic cytokine produced by keratocysts. Arch Oral Biol. 1992;37(11):935–43.CrossRefPubMed
30.
Ogata S et al. Signaling pathways regulating IL-1alpha-induced COX-2 expression. J Dent Res. 2007;86(2):186–91.CrossRefPubMed
31.
Siar CH, Ishak I, Ng KH. Podoplanin, E-cadherin, beta-catenin, and CD44v6 in recurrent ameloblastoma: their distribution patterns and relevance. J Oral Pathol Med. 2015;44(1):51–8.CrossRefPubMed
32.••
Saunders S et al. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol. 1989;108(4):1547–56. Ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib, making a new paradigm for the diagnostic classification and treatment of ameloblastomas.
33.••
Al-Otaibi O et al. Syndecan-1 (CD 138) surface expression marks cell type and differentiation in ameloblastoma, keratocystic odontogenic tumor, and dentigerous cyst. J Oral Pathol Med. 2013;42(2):186–93. Activating FGFR2-RAS-BRAF mutations play a critical role in the pathogenesis of most cases of ameloblastoma. BRAF V600E mutations have both diagnostic and prognostic implications.
34.
Cairns L et al. CD56 (NCAM) expression in ameloblastomas and other odontogenic lesions. Histopathology. 2010;57(4):544–8.CrossRefPubMed
35.
Nakano K, Nagatsuka H, Kawakami T. Wingless-type protein-1 (Wnt-1) expression in primary conventional and unicystic ameloblastomas and their recurrent tumors. J Hard Tissue Biol. 2009;18(2):63–70.CrossRef
36.
Siar CH et al. Differential expression of canonical and non-canonical Wnt ligands in ameloblastoma. J Oral Pathol Med. 2012;41(4):332–9.CrossRefPubMed
37.
González‐Alva P et al. Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med. 2010;39(1):103–9.CrossRefPubMed
38.
Ren C et al. Differential enamel and osteogenic gene expression profiles in odontogenic tumors. Cells Tissues Organs. 2011;194(2–4):296–301.CrossRefPubMed
39.
40.
Brown NA et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014;20(21):5517–26.CrossRefPubMed
41.
Kaminagakura E et al. Detection of cytokeratins in ghost cells of calcifying cystic odontogenic tumor indicates an altered keratinization and hair follicle differentiation for their development. Ann Diagn Pathol. 2013;17(6):514–7.CrossRefPubMed
42.
Ribeiro BF et al. Immunohistochemical expression of matrix metalloproteinases 1, 2, 7, 9, and 26 in the calcifying cystic odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(5):609–15.CrossRefPubMed
43.
44.
Er N et al. Neural cell adhesion molecule and neurothelin expression in human ameloblastoma. J Oral Maxillofac Surg. 2001;59(8):900–3. discussion 904.CrossRefPubMed
45.
Kumamoto H, Ooya K. Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. J Oral Pathol Med. 2006;35(6):345–51.CrossRefPubMed
46.
47.
Barreto DC et al. PTCH gene mutations in odontogenic keratocysts. J Dent Res. 2000;79(6):1418–22.CrossRefPubMed
48.
Andrade FR et al. Expression of bone resorption regulators (RANK, RANKL, and OPG) in odontogenic tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(4):548–55.CrossRefPubMed
49.
Wan PT et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.CrossRefPubMed
50.
Shear M, Speight P. Cysts of the oral and maxillofacial regions. New York: John Wiley & Sons; 2008.
51.
Da Silva MJA et al. Immunohistochemical study of the orthokeratinized odontogenic cyst: a comparison with the odontogenic keratocyst. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94(6):732–7.CrossRefPubMed
52.
Yoshida M et al. Histopathological and immunohistochemical analysis of calcifying odontogenic cysts. J Oral Pathol Med. 2001;30(10):582–8.CrossRefPubMed
53.
Yagyuu T et al. Recurrence of keratocystic odontogenic tumor: clinicopathological features and immunohistochemical study of the Hedgehog signaling pathway. Pathobiology. 2008;75(3):171–6.CrossRefPubMed
54.
55.
Da Silva TA et al. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(3):333–41.CrossRefPubMed
56.
Bologna-Molina R et al. Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma. Pathol Int. 2009;59(4):229–33.CrossRefPubMed
57.
Bello IO et al. Claudins 1, 4, 5, 7 and occludin in ameloblastomas and developing human teeth. J Oral Pathol Med. 2007;36(1):48–54.CrossRefPubMed
58.
59.•
Ribeiro BF et al. Immunoexpression of MMPs-1, −2, and −9 in ameloblastoma and odontogenic adenomatoid tumor. Oral Dis. 2009;15(7):472–7. TGF-beta, a potent EMT inducer, and Slug, a master transcription factor, were highly expressed in KCOT, suggesting EMT might be involved in the locally aggressive behavior of KCOT. CrossRefPubMed
60.
Stone DM et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature. 1996;384(6605):129–34.CrossRefPubMed
61.
Kawabata T et al. Polymorphisms in PTCH1 affect the risk of ameloblastoma. J Dent Res. 2005;84(9):812–6.CrossRefPubMed
62.
Dalati T, Zhou H. Gorlin syndrome with ameloblastoma: a case report and review of literature. Cancer Invest. 2008;26(10):975–6.CrossRefPubMed
63.
Stoelinga PJW. Etiology and pathogenesis of keratocysts. Oral Maxillofac Surg Clin North Am. 2003;15(3):317–24.CrossRefPubMed
64.
Stoelinga PJW. The treatment of odontogenic keratocysts by excision of the overlying, attached mucosa, enucleation, and treatment of the bony defect with Carnoy solution. J Oral Maxillofac Surg. 2005;63(11):1662–6.CrossRefPubMed
65.
Voorsmit RA, Stoelinga PJ, van Haelst UJ. The management of keratocysts. J Maxillofac Surg. 1981;9(4):228–36.CrossRefPubMed
66.
Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2. Proliferation and genetic studies. Oral Oncol. 2002;38(4):323–31.CrossRefPubMed
67.
68.•
Porto LPA et al. E-cadherin regulators are differentially expressed in the epithelium and stroma of keratocystic odontogenic tumors. J Oral Pathol Med. 2016;45(4):302–11.
69.
Zhong WQ et al. Epithelial-mesenchymal transition in keratocystic odontogenic tumor: possible role in locally aggressive behavior. Biomed Res Int. 2015;2015:168089.PubMedPubMedCentral
70.
Cildir SK et al. Delayed eruption of a mandibular primary cuspid associated with compound odontoma. J Contemp Dent Pract. 2005;6(4):152–9.PubMed
71.
Kramer IRH, Pindborg JJ, Shear M. Histological typing of odontogenic tumors. World Health Organization. International Histological Classification of Tumors. 1992.CrossRef
72.
Noffke CE, Chabikuli NJ, Nzima N. Impaired tooth eruption: a review. SADJ. 2005;60(10):422. 424–5.PubMed
73.
74.
Gonzalez-Alva P et al. Podoplanin expression in odontomas: clinicopathological study and immunohistochemical analysis of 86 cases. J Oral Sci. 2011;53(1):67–75.CrossRefPubMed
75.
76.
Ziebart T et al. The original family revisited after 37 years: odontoma-dysphagia syndrome is most likely caused by a microduplication of chromosome 11q13.3, including the FGF3 and FGF4 genes. Clin Oral Investig. 2013;17(1):123–30.CrossRefPubMed
77.
Moleri AB, Moreira LC, Carvalho JJ. Comparative morphology of 7 new cases of calcifying odontogenic cysts. J Oral Maxillofac Surg. 2002;60(6):689–96.CrossRefPubMed
78.
Praetorius F et al. Calcifying odontogenic cyst. Range, variations and neoplastic potential. Acta Odontol Scand. 1981;39(4):227–40.CrossRefPubMed
79.
Buchner A et al. Peripheral (extraosseous) calcifying odontogenic cyst. A review of forty-five cases. Oral Surg Oral Med Oral Pathol. 1991;72(1):65–70.CrossRefPubMed
80.
Gong Y et al. The expression of NF-kappaB, Ki-67 and MMP-9 in CCOT. DGCT and GCOC Oral Oncol. 2009;45(6):515–20.CrossRefPubMed
81.
Sekine S et al. Beta-catenin mutations are frequent in calcifying odontogenic cysts, but rare in ameloblastomas. Am J Pathol. 2003;163(5):1707–12.CrossRefPubMedPubMedCentral
82.
Ahn SG et al. Beta-catenin gene alterations in a variety of so-called calcifying odontogenic cysts. APMIS. 2008;116(3):206–11.CrossRefPubMed
83.
Kaplan I et al. Radiological and clinical features of calcifying epithelial odontogenic tumour. Dentomaxillofac Radiol. 2001;30(1):22–8.CrossRefPubMed
84.
Azevedo RS et al. Calcifying epithelial odontogenic tumor (CEOT): a clinicopathologic and immunohistochemical study and comparison with dental follicles containing CEOT-like areas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(6):759–68.CrossRefPubMed
85.
Crivelini MM et al. Cytokeratins in epithelia of odontogenic neoplasms. Oral Dis. 2003;9(1):1–6.CrossRefPubMed
86.
Crivelini MM et al. Expression of odontogenic ameloblast-associated protein, amelotin, ameloblastin, and amelogenin in odontogenic tumors: immunohistochemical analysis and pathogenetic considerations. J Oral Pathol Med. 2012;41(3):272–80.CrossRefPubMed
87.
Mori M et al. Expression of tenascin in odontogenic tumours. Eur J Cancer B Oral Oncol. 1995;31B(4):275–9.CrossRefPubMed
88.
Zhang L et al. Epithelial expression of SHH signaling pathway in odontogenic tumors. Oral Oncol. 2006;42(4):398–408.CrossRefPubMed
89.
Peacock ZS, Cox D, Schmidt BL. Involvement of PTCH1 mutations in the calcifying epithelial odontogenic tumor. Oral Oncol. 2010;46(5):387–92.CrossRefPubMed
90.
Regezi JA, Kerr DA, Courtney RM. Odontogenic tumors: analysis of 706 cases. J Oral Surg. 1978;36(10):771–8.PubMed
91.
Fujita S, Hideshima K, Ikeda T. Nestin expression in odontoblasts and odontogenic ectomesenchymal tissue of odontogenic tumours. J Clin Pathol. 2006;59(3):240–5.CrossRefPubMedPubMedCentral
92.
Simon EN et al. Odontogenic myxoma: a clinicopathological study of 33 cases. Int J Oral Maxillofac Surg. 2004;33(4):333–7.CrossRefPubMed
93.
Schmidt-Westhausen A et al. Odontogenic myxoma--characterisation of the extracellular matrix (ECM) of the tumour stroma. Eur J Cancer B Oral Oncol. 1994;30B(6):377–80.CrossRefPubMed
94.
95.
Bast BT, Pogrel MA, Regezi JA. The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas. J Oral Maxillofac Surg. 2003;61(12):1463–6.CrossRefPubMed
96.
Sato K et al. Odontogenic myxofibroma with HMGA2 overexpression and HMGA2 rearrangement. Pathol Int. 2010;60(11):760–4.CrossRefPubMed
97.
Carney JA et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985;64(4):270–83.CrossRef
98.
Perdigao PF et al. Molecular and immunohistochemical investigation of protein kinase a regulatory subunit type 1A (PRKAR1A) in odontogenic myxomas. Genes Chromosomes Cancer. 2005;44(2):204–11.CrossRefPubMed
Metadaten
Titel
Benign Odontogenic Tumors: Origins, Immunophenotypic Features, and Genetic Alterations
verfasst von
Chunmiao Jiang
Qilin Xu
Qunzhou Zhang
Steven Wang
Lee R. Carrasco
Anh D. Le
Publikationsdatum
01.06.2016
Verlag
Springer International Publishing
Erschienen in
Current Oral Health Reports / Ausgabe 2/2016
Elektronische ISSN: 2196-3002
DOI
https://doi.org/10.1007/s40496-016-0087-x

Weitere Artikel der Ausgabe 2/2016

Current Oral Health Reports 2/2016 Zur Ausgabe

Oral Neoplasia (F Alawi and A Le, Section Editors)

Immunotherapy for Head and Neck Squamous Cell Carcinoma

Cariology (J Tagami, Section Editor)

The Utility of Chewing Gum in Treating White Spot Lesions

Oral Neoplasia (F Alawi and A Le, Section Editors)

Molecular Markers of Fibro-Osseous Lesions and Osteosarcomas of the Craniofacial Complex—Current Situation and Recent Advances

Oral Neoplasia (F Alawi and A Le, Section Editors)

Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis

Cariology (J Tagami, Section Editor)

The Dental Drug Delivery System for Prevention of Dental Caries

Oral Neoplasia (F Alawi and A Le, Section Editors)

Oral Cancer and Cancer Stem Cells: Relevance to Oral Cancer Risk Factors, Premalignant Lesions, and Treatment

Neu im Fachgebiet Zahnmedizin

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 Vorhofflimmern Nachrichten

Werden Personen mit Vorhofflimmern in der Blanking-Periode nach einer Katheterablation gegen eine bestehende Parodontitis behandelt, verbessert dies die Erfolgsaussichten. Dafür sprechen die Resultate einer prospektiven Untersuchung.

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise